SCHEMBL5540587

SCHEMBL5540587

Cc1c(O)ccc2cccnc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.59
TSHR P16473 2/20 0.59
METAP2 P50579 2/20 0.59
CHRM1 P11229 1/20 0.59
COMT P21964 1/20 0.59
ADRA1A P35348 1/20 0.59
METAP1 P53582 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
KDM4E B2RXH2 4/20 0.58
LMNA P02545 4/20 0.58
MAPT P10636 4/20 0.58
CCR1 P32246 3/20 0.58
CCR5 P51681 3/20 0.58
CCR8 P51685 3/20 0.58
HTT P42858 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
HSP90AA1 P07900 2/20 0.58
GMNN O75496 1/20 0.58
TP53 P04637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063648 0.79 MMP2 (0.63) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL8404537 0.79 LMNA (0.68) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL1286608 0.79 MMP2 (0.63) MMP2TSHRMETAP2CHRM1COMT
Phenanthroline SCHEMBL9343811 0.78 KDM4E (0.84) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL9379959 0.78 MMP2 (0.61) MMP2TSHRMETAP2CHRM1COMT
Phenanthroline SCHEMBL27878295 0.76 KDM4E (0.80) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL3070366 0.76 LMNA (0.63) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL5540582 0.76 LMNA (0.58) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL623096 0.76 LMNA (0.63) MMP2TSHRMETAP2CHRM1COMT
SCHEMBL18848445 0.76 KDM4E (0.58) MMP2TSHRMETAP2CHRM1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11883367-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-01-30 US disclosed
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 US disclosed
EP-4219496-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
US-20230071711-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-03-09 US disclosed
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 US disclosed
EP-3362518-B1 SENSOR DYES FOR REAL-TIME SENSING OF METAL IONS IN AQUEOUS ENVIRONMENTS THE UWM RES FOUNDATION INC (US) 2022-04-27 EP disclosed
EP-3974428-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS Janssen Pharmaceutica NV (BE) 2022-03-30 EP disclosed
EP-3341368-B1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-06 EP disclosed
US-11059850-B2 Spirobicyclic analogues JANSSEN PHARMACEUTICA NV (BE) 2021-07-13 US disclosed
US-20200369707-A1 NOVEL SPIROBICYCLIC ANALOGUES VRIJE UNIVERSITEIT BRUSSEL (BE) 2020-11-26 US disclosed
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-11-19 US disclosed
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 US disclosed
US-20180243328-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-30 US disclosed
WO-2017066672-A1 SENSOR DYES FOR REAL-TIME SENSING OF METAL IONS IN AQUEOUS ENVIRONMENTS UWM RESEARCH FOUNDATION, INC. (US) 2017-04-20 WO disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369707-A1 NOVEL SPIROBICYCLIC ANALOGUES PRMT5, SIRT5, HDAC5 MMP2 4509/4885TSHR 2881/4885METAP2 3331/4885
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 MMP2 4118/4885TSHR 4098/4885METAP2 1468/4885
US-20230071711-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 MMP2 4539/4885TSHR 4434/4885METAP2 2480/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MMP2 4704/4885TSHR 319/4885METAP2 4595/4885
US-11883367-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 MMP2 4506/4885TSHR 4227/4885METAP2 2270/4885
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 MMP2 4258/4885TSHR 4328/4885METAP2 1732/4885
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 MMP2 4530/4885TSHR 4265/4885METAP2 2328/4885
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 MMP2 4118/4885TSHR 4098/4885METAP2 1468/4885
US-11059850-B2 Spirobicyclic analogues PRMT5, HDAC5, SIRT5 MMP2 4259/4885TSHR 3098/4885METAP2 3510/4885
US-20180243328-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 MMP2 4539/4885TSHR 4434/4885METAP2 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.